110 related articles for article (PubMed ID: 18237849)
1. Circulating markers of biliary malignancy: opportunities in proteomics?
Bonney GK; Craven RA; Prasad R; Melcher AF; Selby PJ; Banks RE
Lancet Oncol; 2008 Feb; 9(2):149-58. PubMed ID: 18237849
[TBL] [Abstract][Full Text] [Related]
2. Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis ?
John AR; Haghighi KS; Taniere P; Esmat ME; Tan YM; Bramhall SR
Dig Surg; 2006; 23(5-6):319-24. PubMed ID: 17170527
[TBL] [Abstract][Full Text] [Related]
3. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
[TBL] [Abstract][Full Text] [Related]
4. Astronomically high CA 19-9 in a patient with a benign lesion.
Rao NA; Satyaprakash BS
S Afr J Surg; 2013 Oct; 51(4):151. PubMed ID: 24209706
[No Abstract] [Full Text] [Related]
5. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
Patel AH; Harnois DM; Klee GG; LaRusso NF; Gores GJ
Am J Gastroenterol; 2000 Jan; 95(1):204-7. PubMed ID: 10638584
[TBL] [Abstract][Full Text] [Related]
6. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S
Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299
[TBL] [Abstract][Full Text] [Related]
7. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels.
Furmanczyk PS; Grieco VS; Agoff SN
Am J Clin Pathol; 2005 Sep; 124(3):355-60. PubMed ID: 16191503
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma.
Tangkijvanich P; Thong-ngam D; Theamboonlers A; Hanvivatvong O; Kullavanijaya P; Poovorawan Y
Hepatogastroenterology; 2004; 51(55):15-9. PubMed ID: 15011822
[TBL] [Abstract][Full Text] [Related]
9. A novel carbohydrate antigen expression during development of Opisthorchis viverrini- associated cholangiocarcinoma in golden hamster: a potential marker for early diagnosis.
Sawanyawisuth K; Silsirivanit A; Kunlabut K; Tantapotinan N; Vaeteewoottacharn K; Wongkham S
Parasitol Int; 2012 Mar; 61(1):151-4. PubMed ID: 21784171
[TBL] [Abstract][Full Text] [Related]
10. Assessment of bile and serum mucin5AC in cholangiocarcinoma: diagnostic performance and biologic significance.
Danese E; Ruzzenente O; Ruzzenente A; Iacono C; Bertuzzo F; Gelati M; Conci S; Bendinelli S; Bonizzato G; Guglielmi A; Salvagno GL; Lippi G; Guidi GC
Surgery; 2014 Nov; 156(5):1218-24. PubMed ID: 25151557
[TBL] [Abstract][Full Text] [Related]
11. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.
Metzger J; Negm AA; Plentz RR; Weismüller TJ; Wedemeyer J; Karlsen TH; Dakna M; Mullen W; Mischak H; Manns MP; Lankisch TO
Gut; 2013 Jan; 62(1):122-30. PubMed ID: 22580416
[TBL] [Abstract][Full Text] [Related]
12. Staging for intrahepatic cholangiocarcinoma.
Kokudo N; Arita J
Liver Int; 2010 Aug; 30(7):931-3. PubMed ID: 20408948
[No Abstract] [Full Text] [Related]
13. Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma.
Rucksaken R; Khoontawad J; Roytrakul S; Pinlaor P; Hiraku Y; Wongkham C; Pairojkul C; Boonmars T; Pinlaor S
Cancer Biomark; 2012; 12(2):81-95. PubMed ID: 23396253
[TBL] [Abstract][Full Text] [Related]
14. Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up.
Charatcharoenwitthaya P; Lindor KD
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):32-6. PubMed ID: 17234554
[No Abstract] [Full Text] [Related]
15. A novel serum carbohydrate marker on mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma.
Silsirivanit A; Araki N; Wongkham C; Pairojkul C; Narimatsu Y; Kuwahara K; Narimatsu H; Wongkham S; Sakaguchi N
Cancer; 2011 Aug; 117(15):3393-403. PubMed ID: 21287531
[TBL] [Abstract][Full Text] [Related]
16. [Prognosis of 84 intrahepatic cholangiocarcinoma patients].
Li FH; Chen XQ; Luo HY; Li YH; Wang F; Qiu MZ; Teng KY; Li ZH; Xu RH
Ai Zheng; 2009 May; 28(5):528-32. PubMed ID: 19624884
[TBL] [Abstract][Full Text] [Related]
17. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis.
Boberg KM; Jebsen P; Clausen OP; Foss A; Aabakken L; Schrumpf E
J Hepatol; 2006 Oct; 45(4):568-74. PubMed ID: 16879890
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
Li YG; Zhang N
Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
[TBL] [Abstract][Full Text] [Related]
20. Primary sclerosing cholangitis and malignancy.
Boberg KM; Lind GE
Best Pract Res Clin Gastroenterol; 2011 Dec; 25(6):753-64. PubMed ID: 22117640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
